@article{1957ae900c0d49799a182912ac7b0e6d,
title = "AD-NET: Age-adjust neural network for improved MCI to AD conversion prediction",
abstract = "The prediction of Mild Cognitive Impairment (MCI) patients who are at higher risk converting to Alzheimer's Disease (AD) is critical for effective intervention and patient selection in clinical trials. Different biomarkers including neuroimaging have been developed to serve the purpose. With extensive methodology development efforts on neuroimaging, an emerging field is deep learning research. One great challenge facing deep learning is the limited medical imaging data available. To address the issue, researchers explore the use of transfer learning to extend the applicability of deep models on neuroimaging research for AD diagnosis and prognosis. Existing transfer learning models mostly focus on transferring the features from the pre-training into the fine-tuning stage. Recognizing the advantages of the knowledge gained during the pre-training, we propose an AD-NET (Age-adjust neural network) with the pre-training model serving two purposes: extracting and transferring features; and obtaining and transferring knowledge. Specifically, the knowledge being transferred in this research is an age-related surrogate biomarker. To evaluate the effectiveness of the proposed approach, AD-NET is compared with 8 classification models from literature using the same public neuroimaging dataset. Experimental results show that the proposed AD-NET outperforms the competing models in predicting the MCI patients at risk for conversion to the AD stage.",
keywords = "AD, Biomarker, Deep learning, MCI, Transfer learning",
author = "Fei Gao and Hyunsoo Yoon and Yanzhe Xu and Dhruman Goradia and Ji Luo and Teresa Wu and Yi Su",
note = "Funding Information: This work is supported in part by R01AG031581, P30AG019610, DHS and the State of Arizona. Arizona Department of Health Services (ADHS), United States Grant No. CTR040636 (previously ADHS Grant No. ADHS14-052688). Dr. Su is also funded by BrightFocus Foundation ADR A2017272S, Alzheimer's Association AARG-17-532945. The funding sources did not play a role in study design, the collection, analysis and interpretation of data, writing of the report; or in the decision to submit the article for publication. Data collection and sharing for this project was funded by the Alzheimer's Disease Neuroimaging Initiative (ADNI) (National Institutes of Health Grant U01 AG024904) and DOD ADNI (Department of Defense award number W81XWH-12-2-0012). ADNI is funded by the National Institute on Aging, the National Institute of Biomedical Imaging and Bioengineering, and through generous contributions from the following: AbbVie, Alzheimer's Association; Alzheimer's Drug Discovery Foundation; Araclon Biotech; BioClinica, Inc.; Biogen; Bristol-Myers Squibb Company; CereSpir, Inc.; Cogstate; Eisai Inc.; Elan Pharmaceuticals, Inc.; Eli Lilly and Company; EuroImmun; F. Hoffmann-La Roche Ltd and its affiliated company Genentech, Inc.; Fujirebio; GE Healthcare; IXICO Ltd.; Janssen Alzheimer Immunotherapy Research & Development, LLC.; Johnson & Johnson Pharmaceutical Research & Development LLC.; Lumosity; Lundbeck; Merck & Co. Inc.; Meso Scale Diagnostics, LLC.; NeuroRx Research; Neurotrack Technologies; Novartis Pharmaceuticals Corporation; Pfizer Inc.; Piramal Imaging; Servier; Takeda Pharmaceutical Company; and Transition Therapeutics. The Canadian Institutes of Health Research is providing funds to support ADNI clinical sites in Canada. Private sector contributions are facilitated by the Foundation for the National Institutes of Health (www.fnih.org). The grantee organization is the Northern California Institute for Research and Education, and the study is coordinated by the Alzheimer's Therapeutic Research Institute at the University of Southern California. ADNI data are disseminated by the Laboratory for Neuro Imaging at the University of Southern California. Funding Information: This work is supported in part by R01AG031581 , P30AG019610 , DHS and the State of Arizona . Arizona Department of Health Services (ADHS) , United States Grant No. CTR040636 (previously ADHS Grant No. ADHS14-052688). Dr. Su is also funded by BrightFocus Foundation ADR A2017272S, Alzheimer{\textquoteright}s Association AARG-17-532945. The funding sources did not play a role in study design, the collection, analysis and interpretation of data, writing of the report; or in the decision to submit the article for publication. Funding Information: Data collection and sharing for this project was funded by the Alzheimer's Disease Neuroimaging Initiative (ADNI) (National Institutes of Health Grant U01 AG024904) and DOD ADNI (Department of Defense award number W81XWH-12-2-0012). ADNI is funded by the National Institute on Aging, the National Institute of Biomedical Imaging and Bioengineering, and through generous contributions from the following: AbbVie, Alzheimer{\textquoteright}s Association; Alzheimer{\textquoteright}s Drug Discovery Foundation; Araclon Biotech; BioClinica, Inc.; Biogen; Bristol-Myers Squibb Company; CereSpir, Inc.; Cogstate; Eisai Inc.; Elan Pharmaceuticals, Inc.; Eli Lilly and Company; EuroImmun; F. Hoffmann-La Roche Ltd and its affiliated company Genentech, Inc.; Fujirebio; GE Healthcare; IXICO Ltd.; Janssen Alzheimer Immunotherapy Research & Development, LLC.; Johnson & Johnson Pharmaceutical Research & Development LLC.; Lumosity; Lundbeck; Merck & Co., Inc.; Meso Scale Diagnostics, LLC.; NeuroRx Research; Neurotrack Technologies; Novartis Pharmaceuticals Corporation; Pfizer Inc.; Piramal Imaging; Servier; Takeda Pharmaceutical Company; and Transition Therapeutics. The Canadian Institutes of Health Research is providing funds to support ADNI clinical sites in Canada. Private sector contributions are facilitated by the Foundation for the National Institutes of Health (www.fnih.org). The grantee organization is the Northern California Institute for Research and Education, and the study is coordinated by the Alzheimer{\textquoteright}s Therapeutic Research Institute at the University of Southern California. ADNI data are disseminated by the Laboratory for Neuro Imaging at the University of Southern California. Publisher Copyright: {\textcopyright} 2020 The Authors",
year = "2020",
doi = "10.1016/j.nicl.2020.102290",
language = "English (US)",
volume = "27",
journal = "NeuroImage: Clinical",
issn = "2213-1582",
publisher = "Elsevier BV",
}